IL6 and melanoma: Another study has emphasized that circulating B lymphocytes produce tumour necrosis factor α (TNF-α) and/or IL-6, these being associated with tumour unresponsiveness and poor survival of melanoma patients who underwent anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) antibody therapy [147].